Alzamend Neuro Files 8-K for Bylaws, Exhibits

Ticker: ALZN · Form: 8-K · Filed: Mar 3, 2025 · CIK: 1677077

Alzamend Neuro, INC. 8-K Filing Summary
FieldDetail
CompanyAlzamend Neuro, INC. (ALZN)
Form Type8-K
Filed DateMar 3, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, filings, financials

TL;DR

Alzamend Neuro filed an 8-K on 3/3/25 for bylaw changes and financial docs.

AI Summary

Alzamend Neuro, Inc. filed an 8-K on March 3, 2025, reporting amendments to its Articles of Incorporation or Bylaws and submitting financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Atlanta, GA, operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing indicates corporate governance updates and the submission of important financial and operational documents, providing transparency to investors.

Risk Assessment

Risk Level: low — This is a routine filing for corporate updates and document submission, not indicating immediate financial distress or significant operational changes.

Key Numbers

Key Players & Entities

FAQ

What specific amendments were made to Alzamend Neuro's Articles of Incorporation or Bylaws?

The filing indicates amendments were made, but the specific details of these amendments are not provided in the summary information.

What types of financial statements and exhibits were filed?

The filing confirms the submission of financial statements and exhibits, but the specific content is not detailed in the provided text.

When was Alzamend Neuro, Inc. incorporated?

Alzamend Neuro, Inc. was incorporated in Delaware.

What is Alzamend Neuro's primary business sector?

Alzamend Neuro operates in the Pharmaceutical Preparations sector, with SIC code 2834.

Where are Alzamend Neuro's principal executive offices located?

The company's principal executive offices are located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 3, 2025 regarding Alzamend Neuro, Inc. (ALZN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing